* MAOIs — hyperserotonergia (serotonin syndrome), potentially lethal hypertensive crisis * 5-HT1 receptor agonists — coronary vasoconstriction with risk of angina pectoris and myocardial infarction * Epinephrine, norepinephrine (also in local anesthesia) — hypertensive crisis and/or possible cardiac arrhythmia * Clonidine — antihypertensive action of clonidine may be antagonized * Digitalis — hemodynamic actions increased * Triptans — there have been rare postmarketing reports of hyperserotonergia (serotonin syndrome). If concomitant treatment of<unk>  with a triptan is clinically warranted, careful observation of patient is advised when starting or increasing dosages. * Alcohol — no interactions known; however, because<unk>  can cause mild elevation of liver enzymes, caution is recommended; the FDA advises against the concomitant use of alcohol and<unk>
Milnacipran
Levomilnacipran
Tezacaftor
Damoctocog alfa pegol
Glysobuzole
Amivantamab
Naloxegol
Glybuzole